PBM — PSYENCE BIOMEDICAL LTD.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1985062 ·
Ontario, Canada
Last close
$4.22
Market Cap
$16.10M
52W High
$5.00
52W Low
$2.62
ADV30
120,556
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2025 | 0 | — | -1,506,307 | -753,254 | 12,810,145 | 7,149,985 | 943,068 |
| Sep 2024 | 0 | — | -1,157,118 | 141,473 | 2,253,498 | 1,932,519 | 3,508,604 |
Balance + Analyst (yfinance extras)
Retained Earnings
$-58,439,936
Inventory
—
Receivables
$174,187
ST Investments
—
EBIT TTM
$-750,501
Pretax Income TTM
$-753,254
Interest Exp TTM
$2,753
Analysts
—
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | -5,945,264 | -6,936,421 | 17,567,320 | 623,190 | — | -8,143,007 |
| Mar 2025 | 0 | -3,663,022 | 1,011,790 | 7,316,370 | 594,366 | — | -3,734,238 |
| Mar 2024 | 0 | -43,354,085 | -51,159,048 | 1,132,159 | 12,104,699 | — | -2,945,365 |
| Mar 2023 | 0 | -3,234,869 | -3,206,403 | 1,590,255 | 1,790,700 | — | -1,592,080 |
| Mar 2022 | — | — | — | — | — | — | — |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| OTLC | Oncotelic Therapeutics, Inc. | $16.01M | $0.04 | — |
| MDCX | Medicus Pharma Ltd. | $16.26M | $0.26 | — |
| CMMB | Chemomab Therapeutics Ltd. | $15.90M | $2.17 | — |
| LSTA | LISATA THERAPEUTICS, INC. | $15.86M | $1.76 | — |
| CTXR | Citius Pharmaceuticals, Inc. | $15.80M | $0.58 | — |
News headlines (Yahoo Finance, 1h cache)
Psyence BioMed Welcomes U.S. Administration’s Latest Action to Accelerate Ibogaine Development
2026-08-18 21:23 · Yahoo
Psyence BioMed Announces U.S. Strategic Engagement Initiative Focused on GMP Ibogaine Research and Manufacturing
2026-05-15 13:15 · Yahoo
Weekly Roundup on the Cannabis Sector & Psychedelic Sector
2026-04-27 13:16 · Yahoo
Psyence BioMed Initiates Patient Dosing in Phase IIb Trial Evaluating NPX-5 for Adjustment Disorder
2026-04-23 11:00 · Yahoo
Psyence BioMed Positioned as World's only Licensed Pharmaceutical Grade Ibogaine Supplier at Source
2026-04-20 11:42 · Yahoo
Trump Trade: President to sign order on psychedelic used for PTSD
2026-04-17 21:56 · Yahoo
Psyence BioMed Welcomes U.S. Executive Action to Advance Research into Ibogaine
2026-04-17 13:15 · Yahoo
Pacific Bay & Aurwest Sign Weaver Gold Property Definitive Option/JV Agreement
2026-04-14 17:17 · Yahoo
Psyence BioMed Expands Australian Clinical Site Network to Five Sites, Advancing NPX-5–Supported Clinical Activities
2026-04-08 13:15 · Yahoo
Corporate Update: Psyence BioMed Advances Vertically Integrated Pharmaceutical Platform Following PsyLabs Export Milestone
2026-03-11 13:15 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.